CRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective lowered by Citigroup from $89.00 to $82.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Truist Financial increased their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. The Goldman Sachs Group dropped their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $52.29 on Tuesday. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $91.10. The firm has a market capitalization of $4.46 billion, a PE ratio of -18.48 and a beta of 1.67. The stock has a fifty day simple moving average of $41.89 and a two-hundred day simple moving average of $45.98.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. On average, sell-side analysts forecast that CRISPR Therapeutics will post -5.08 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Capital Market Strategies LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter worth about $461,000. KBC Group NV boosted its holdings in CRISPR Therapeutics by 2,047.4% in the fourth quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after acquiring an additional 57,696 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after acquiring an additional 22,583 shares in the last quarter. Geode Capital Management LLC boosted its holdings in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Finally, State Street Corp boosted its holdings in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.